Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CLLS with free AI briefings, catalyst countdowns, and dilution alerts.

CLLS · Cellectis S.A.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$146.7M Cash on Hand
CF+ Cash Runway
Follow CLLS by email Get an email when CLLS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CLLS, unsubscribe in one click. Privacy

📣 What CLLS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Etivelcabtagene Erigedleucel B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1/2 · NCT05607420 Recruiting
Lasmecabtagene Timgedleucel (UCART22) B-cell Acute Lymphoblastic Leukemia Phase 1/2 · NCT04150497 Active not recruiting
Allogeneic CD123-specific Universal… Acute Myeloid Leukaemia Phase 1 · NCT04106076 Withdrawn
UCART123v1.2 Relapsed/Refractory Acute Myeloid Leukemia Phase 1 · NCT03190278 Active not recruiting
Allogeneic CS1-specific Universal… Relapsed/Refractory Multiple Myeloma Phase 1 · NCT04142619 Terminated

Also used in these trials (approved or third-party drugs, not CLLS's own candidates): Alemtuzumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CLLS holds $146.7M in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 20 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CLLS files for a raise →

👥 Who Owns CLLS

Insiders Form 4 data not loaded yet Other 5%+ holders 89.4% Institutions (35 holders) 10.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
AstraZeneca PLC 5%+ holder (13D) 44,000,000 61.32% 2025-01-23
Caisse des Depots 5%+ holder (13D) 10,599,440 14.77% 2025-12-03
Bpifrance Participations S.A. 5%+ holder (13D) 9,559,534 13.32% 2026-10-28

Share count 71,751,201 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CLLS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLLS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.